HeartSciences annual stock-based compensation
2022
2023
2024
2025
2026
HeartSciences Stock-Based Compensation Growth & History (HSCS)
HeartSciences's stock-based compensation was $1.3M for fiscal 2026.
View full HeartSciences company overviewHeartSciences annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-04-30 | $1.3M | $1.1M | +425.20% |
| 2025 | 2025-04-30 | $249,884 | −$155,141 | −38.30% |
| 2024 | 2024-04-30 | $405,025 | $156,718 | +63.11% |
| 2023 | 2023-04-30 | $248,307 | $179,911 | +263.04% |
| 2022 | 2022-04-30 | $68,396 | — | — |
HeartSciences quarterly stock-based compensation
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q3.26
Q4.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q4 2026 | 2026-04-30 | $324,841 | $228,896 | +238.57% |
| Q3 2026 | 2026-01-31 | $376,100 | $321,276 | +586.01% |
| Q2 2026 | 2025-10-31 | $436,884 | $392,323 | +880.42% |
| Q1 2026 | 2025-07-31 | $174,558 | $120,004 | +219.97% |
| Q4 2025 | 2025-04-30 | $95,945 | $17,498 | +22.31% |
| Q3 2025 | 2025-01-31 | $54,824 | −$41,268 | −42.95% |
| Q2 2025 | 2024-10-31 | $44,561 | −$61,279 | −57.90% |
| Q1 2025 | 2024-07-31 | $54,554 | −$70,092 | −56.23% |
| Q4 2024 | 2024-04-30 | $78,447 | −$20,707 | −20.88% |
| Q3 2024 | 2024-01-31 | $96,092 | $94,579 | +6251.09% |
| Q2 2024 | 2023-10-31 | $105,840 | $103,922 | +5418.25% |
| Q1 2024 | 2023-07-31 | $124,646 | −$21,076 | −14.46% |
| Q4 2023 | 2023-04-30 | $99,154 | — | — |
| Q3 2023 | 2023-01-31 | $1,513 | −$114,319 | −98.69% |
| Q2 2023 | 2022-10-31 | $1,918 | $1,084 | +129.98% |
| Q1 2023 | 2022-07-31 | $145,722 | $144,139 | +9105.43% |
| Q3 2022 | 2022-01-31 | $115,832 | — | — |
| Q2 2022 | 2021-10-31 | $834 | — | — |
| Q1 2022 | 2021-07-31 | $1,583 | — | — |
HeartSciences stock-based compensation trends
Between the periods ended 2022-04-30 and 2026-04-30, HeartSciences's stock-based compensation increased from $68,396 to $1.3M, a change of $1.2M. The latest reported quarter, Q4 2026, shows $324,841.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review HeartSciences source filings ↗